Back to search

Netherlands· NL-133a15690507

Namuscla 167 mg harde capsules

A other drugs for disorders of the musculo-skeletal system product containing mexiletinehydrochloride, registered in Netherlands by Lupin (Europe) Limited. The same ATC class is registered in 2 of our 19 countries.

ATC M09AX

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedNamuscla 167 mg harde capsulesATCM09AXREGISTER NO.NL-133a15690507PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Mexiletinehydrochloride is registered in 2 of 19 countries.

Countries holding a registration under ATC M09AX (other drugs for disorders of the musculo-skeletal system), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 1 of them publish a price we can compare per daily dose

Mexiletinehydrochloride · ATC M09AX

2 / 19 countries

  • Netherlands
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MEXILETINEHYDROCHLORIDE
Manufacturer
Lupin (Europe) Limited
Country
Netherlands (NL)
ATC code
M09AX
ATC class
Other drugs for disorders of the musculo-skeletal system
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/18/1325

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mexiletinehydrochloride in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mexiletinehydrochloride products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Germany · Zunmyro, Zunmyro 200 Mg Hartkapseln
  • Denmark · Dopital
  • Finland · Dopital
  • France · Makmorsa
  • United Kingdom (Northern Ireland) · Mexiletine Hydrochloride Clinigen Healthcare, Mexiletine Hydrochloride Waymade
  • Hungary · Ritalmex
  • Norway · Dopital
  • Sweden · Dopital

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/64a71852-a808-4912-b85d-e232026de365
GET /v1/drugs/64a71852-a808-4912-b85d-e232026de365?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/namuscla-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Other Drugs For Disorders Of The Musculo-Skel Syst",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp121562",
  "excipients": [
    "GELATINE (E 441)",
    "IJZEROXIDE ROOD  (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "MEXILETINEHYDROCHLORIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/12/18",
  "procedure_number": "EMEA/H/C/004584",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1325",
  "additional_monitoring": "N"
}

See everything about mexiletinehydrochloride.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.